Get the Stockscreener App
234.56
1.76%
4.06
After Hours:
234.56
Alnylam Pharmaceuticals Inc stock is traded at $234.56, with a volume of 601.33K.
It is up +1.76% in the last 24 hours and down -7.33% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$230.50
Open:
$230.48
24h Volume:
601.33K
Relative Volume:
0.69
Market Cap:
$31.06B
Revenue:
$2.25B
Net Income/Loss:
$-278.16M
P/E Ratio:
-108.09
EPS:
-2.17
Net Cash Flow:
$-42.59M
1W Performance:
+3.66%
1M Performance:
-7.33%
6M Performance:
-20.96%
1Y Performance:
+61.41%
1-Day Range:
$228.96
$235.12
1-Week Range:
$220.54
$242.15
52-Week Range:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating - marketscreener.com
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results | ALNY Stock News - GuruFocus
Earnings Preview: RNAi Leader Alnylam Set to Unveil Q1 2025 Performance May 1What to Watch - Stock Titan
Coagulation Factor Deficiency Therapeutics Market Size in 7MM - openPR.com
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years - Benzinga
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool
RNAi Therapeutics and Technology Market Key Players Analysis - openPR.com
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires? - Insider Monkey
High Growth Tech Stocks In US With Potential For Expansion - simplywall.st
Morgan Stanley Lowers Alnylam (ALNY) Price Target Amid Earnings Preview | ALNY Stock News - GuruFocus
Cns Specific Antisense Oligonucleotide Market Is Booming - openPR.com
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? - MSN
Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive - Endpoints News
Alnylam at 24th Annual Needham Conference: Strategic Growth in Focus By Investing.com - Investing.com Australia
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires? - Insider Monkey
Is Alnylam Pharmaceuticals Gaining or Losing Market Support? - Benzinga
Primary Hyperoxaluria Market to Expand Significantly by 2034, - openPR.com
H.C. Wainwright maintains $500 target on Alnylam stock By Investing.com - Investing.com UK
Alnylam Pharmaceuticals, Inc. (ALNY) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Alnylam and Tekmira Restructure Relationship and Settle All Litigation - AOL.com
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference - BioSpace
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States - Yahoo Finance
Rnai Technology Market Generated Opportunities, Future Scope - openPR.com
RNAi Leader Alnylam Reveals Growth Strategy at Major Healthcare Conference - Stock Titan
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know - Benzinga
Pfizer's $11.6 billion Biohaven buy could spark more biotech deals - MarketScreener
Sanofi adds to hemophilia arsenal with FDA nod for Qfitlia - BioWorld MedTech
Sanofi, Alnylam win first RNAi approval for hemophilia A and B - PharmaLive
Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment - MarketScreener
Stifel cuts Alnylam stock price target to $300 from $345 By Investing.com - Investing.com UK
Scotiabank raises Alnylam stock target to $342, maintains rating By Investing.com - Investing.com UK
Stifel raises Alnylam stock price target to $345 on FDA nod - Investing.com India
Redburn-Atlantic sets $353 target on Alnylam stock with Buy rating - Investing.com India
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B - BioSpace
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025 - BioSpace
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip - simplywall.st
Groundbreaking HELIOS-B Trial: AMVUTTRA Proves Major Breakthrough for Heart Disease Patients - Stock Titan
Alnylam’s Qfitlia gets FDA nod for hemophilia treatment By Investing.com - Investing.com South Africa
FDA approves first-of-its-kind RNA drug for hemophilia - BioPharma Dive
Alnylam’s Qfitlia gets FDA nod for hemophilia treatment - Investing.com India
Revolutionary Hemophilia Treatment Achieves 90% Bleed Reduction in FDA Approval - Stock Titan
FDA approves Sanofi’s RNAi drug for hemophilia A and B - Endpoints News
Alnylam CEO's compensation package continues to grow - NBC Boston
Alnylam CEO’s compensation package continues to grow - The Business Journals
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Yahoo Finance
Transthyretin Amyloidosis Treatment Market Detailed In New - openPR
Alnylam Pharmaceuticals director David Pyott sells $2.2 million in stock By Investing.com - Investing.com Australia
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? - MSN
Alnylam Pharmaceuticals director David Pyott sells $2.2 million in stock - Investing.com India
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com India
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):